Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for ≥24 Weeks in People With CF and ≥1 F508del Allele: Interim Results of an Open-Label Phase Three Clinical Trial.
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
8
References
25
Citations
NaN
KQI